BACKGROUND: In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care. PATIENTS AND METHODS: The Prostate Cancer Clinical Research Information System is a relational database. Data are entered from multiple sources, including medical records, institutional laboratory, patient registration, pharmacy systems, and clinician forms. The history, design, and operational characteristics of the database are described. Issues regarding necessary staffing and funding of databases are reviewed. RESULTS: Four thousand two hundred forty-six patients have information in the Prostate Cancer Clinical Research Information System. Mean age of patients is 62 years, and 89% are white. Seventy-one percent of patients presented at diagnosis with T1 or T2 disease, and 78% had biopsy Gleason scores of <or=7, 8-10 in 18%. Median prostate-specific antigen level at diagnosis was 7 ng/mL, and 77% of patients presented with increased prostate-specific antigen as a trigger symptom. Sixty-four percent of patients presented to our clinic having had no previous treatment for prostate cancer. The majority of approached patients provided consent for collection of clinical data, blood, and tissue. Quality control assessments demonstrate high levels of concordance among data entry personnel. CONCLUSION: Clinical databases are difficult to implement and maintain; however, they represent a valuable resource, particularly when linked to blood and tissue banks. Elements needed for a successful clinical database include engagement of clinicians, utility for research, and the ability to integrate with legacy systems. As cancer centers develop such databases, lessons learned from each experience should be shared in order to optimize the process.
BACKGROUND: In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care. PATIENTS AND METHODS: The Prostate Cancer Clinical Research Information System is a relational database. Data are entered from multiple sources, including medical records, institutional laboratory, patient registration, pharmacy systems, and clinician forms. The history, design, and operational characteristics of the database are described. Issues regarding necessary staffing and funding of databases are reviewed. RESULTS: Four thousand two hundred forty-six patients have information in the Prostate Cancer Clinical Research Information System. Mean age of patients is 62 years, and 89% are white. Seventy-one percent of patients presented at diagnosis with T1 or T2 disease, and 78% had biopsy Gleason scores of <or=7, 8-10 in 18%. Median prostate-specific antigen level at diagnosis was 7 ng/mL, and 77% of patients presented with increased prostate-specific antigen as a trigger symptom. Sixty-four percent of patients presented to our clinic having had no previous treatment for prostate cancer. The majority of approached patients provided consent for collection of clinical data, blood, and tissue. Quality control assessments demonstrate high levels of concordance among data entry personnel. CONCLUSION: Clinical databases are difficult to implement and maintain; however, they represent a valuable resource, particularly when linked to blood and tissue banks. Elements needed for a successful clinical database include engagement of clinicians, utility for research, and the ability to integrate with legacy systems. As cancer centers develop such databases, lessons learned from each experience should be shared in order to optimize the process.
Authors: Kathryn L Penney; Saumyadipta Pyne; Fredrick R Schumacher; Jennifer A Sinnott; Lorelei A Mucci; Peter L Kraft; Jing Ma; William K Oh; Tobias Kurth; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; David J Hunter; Matthew L Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-26 Impact factor: 4.254
Authors: Miyako Abe; Wanling Xie; Meredith M Regan; Irena B King; Meir J Stampfer; Philip W Kantoff; William K Oh; June M Chan Journal: BJU Int Date: 2011-01 Impact factor: 5.588
Authors: Fangfang Qu; Wanling Xie; Mari Nakabayashi; Haitao Zhang; Seong Ho Jeong; Xiaodong Wang; Kazumasa Komura; Christopher J Sweeney; Oliver Sartor; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Clin Cancer Res Date: 2016-08-03 Impact factor: 12.531
Authors: Atish D Choudhury; Anna C Schinzel; Maura B Cotter; Rosina T Lis; Katherine Labella; Ying Jie Lock; Francesca Izzo; Isil Guney; Michaela Bowden; Yvonne Y Li; Jinal Patel; Emily Hartman; Steven A Carr; Monica Schenone; Jacob D Jaffe; Philip W Kantoff; Peter S Hammerman; William C Hahn Journal: Cancer Res Date: 2016-11-29 Impact factor: 12.701
Authors: Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Mark M Pomerantz; Lillian Werner; Wanling Xie; Meredith M Regan; Gwo-Shu Mary Lee; Tong Sun; Carolyn Evan; Gillian Petrozziello; Mari Nakabayashi; William K Oh; Philip W Kantoff; Matthew L Freedman Journal: Cancer Prev Res (Phila) Date: 2011-03-02
Authors: Xiaosai Yao; Atish D Choudhury; Yvonne J Yamanaka; Viktor A Adalsteinsson; Todd M Gierahn; Christina A Williamson; Carla R Lamb; Mary-Ellen Taplin; Mari Nakabayashi; Matthew S Chabot; Tiantian Li; Gwo-Shu M Lee; Jesse S Boehm; Philip W Kantoff; William C Hahn; K Dane Wittrup; J Christopher Love Journal: Integr Biol (Camb) Date: 2014-02-13 Impact factor: 2.192
Authors: R R McKay; L Werner; M Fiorillo; M Nakabayashi; P W Kantoff; M-E Taplin Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554
Authors: Li Jia; Gilad Landan; Mark Pomerantz; Rami Jaschek; Paula Herman; David Reich; Chunli Yan; Omar Khalid; Phil Kantoff; William Oh; J Robert Manak; Benjamin P Berman; Brian E Henderson; Baruch Frenkel; Christopher A Haiman; Matthew Freedman; Amos Tanay; Gerhard A Coetzee Journal: PLoS Genet Date: 2009-08-14 Impact factor: 5.917